Literature DB >> 35877475

Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.

Yue Zhan1,2, Xiaolei Zhou1, Sylvain Peuget1, Madhurendra Singh1, Brian D Peyser3, Zhimin Fan2, Galina Selivanova1.   

Abstract

Reactivation of p53 tumor-suppressor function by small molecules is an attractive strategy to defeat cancer. A potent p53-reactivating molecule RITA, which triggers p53-dependent apoptosis in human tumor cells in vitro and in vivo, exhibits p53-independent cytotoxicity due to modifications by detoxification enzyme Sulfotransferase 1A1 (SULT1A1), producing a reactive carbocation. Several synthetic modifications to RITA's heterocyclic scaffold lead to higher energy barriers for carbocation formation. In this study, we addressed the question whether RITA analogs NSC777196 and NSC782846 can induce p53-dependent apoptosis without SULT1A1-dependent DNA damage. We found that RITA analog NSC782846, but not NSC777196, induced p53-regulated genes, targeted oncogene addiction, and killed cancer cells upon p53 reactivation, but without induction of DNA damage and inhibition RNA pol II. Our results might demonstrate a method for designing more specific and potent RITA analogs to accelerate translation of p53-targeting compounds from laboratory bench to clinic. ©2022 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35877475      PMCID: PMC9538593          DOI: 10.1158/1535-7163.MCT-22-0119

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.009


  36 in total

1.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

2.  Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis.

Authors:  Vera V Grinkevich; Fedor Nikulenkov; Yao Shi; Martin Enge; Wenjie Bao; Alena Maljukova; Angela Gluch; Alexander Kel; Olle Sangfelt; Galina Selivanova
Journal:  Cancer Cell       Date:  2009-05-05       Impact factor: 31.743

3.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

Review 4.  Precision oncology: origins, optimism, and potential.

Authors:  Vinay Prasad; Tito Fojo; Michael Brada
Journal:  Lancet Oncol       Date:  2016-02       Impact factor: 41.316

5.  Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

Authors:  Natalia Issaeva; Przemyslaw Bozko; Martin Enge; Marina Protopopova; Lisette G G C Verhoef; Maria Masucci; Aladdin Pramanik; Galina Selivanova
Journal:  Nat Med       Date:  2004-11-21       Impact factor: 53.440

6.  Determination of sulfotransferase forms involved in the metabolic activation of the genotoxicant 1-hydroxymethylpyrene using bacterially expressed enzymes and genetically modified mouse models.

Authors:  Carolin Bendadani; Walter Meinl; Bernhard Monien; Gisela Dobbernack; Simone Florian; Wolfram Engst; Tobias Nolden; Heinz Himmelbauer; Hansruedi Glatt
Journal:  Chem Res Toxicol       Date:  2014-05-22       Impact factor: 3.739

Review 7.  p53: fighting cancer.

Authors:  Galina Selivanova
Journal:  Curr Cancer Drug Targets       Date:  2004-08       Impact factor: 3.428

8.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

Review 9.  Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.

Authors:  Liz J Hernández Borrero; Wafik S El-Deiry
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2021-04-29       Impact factor: 11.414

10.  Identification and targeting of selective vulnerability rendered by tamoxifen resistance.

Authors:  Madhurendra Singh; Xiaolei Zhou; Xinsong Chen; Gema Sanz Santos; Sylvain Peuget; Qing Cheng; Ali Rihani; Elias S J Arnér; Johan Hartman; Galina Selivanova
Journal:  Breast Cancer Res       Date:  2020-07-29       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.